News

In a new interview from ACC 2022, Florian Rader, MD discusses the potential of the new medication for HCM and the need to monitor safety signals over the long-term.

New phase 1 APOLLO data show the investigative single-dose siRNA infusion may address an inherent risk factor for severe cardiovascular events.

Larry Allen, MD, explains the significance of introducing SGLT-2 inhibitor recommendations to various stages of heart failure treatment and prevention guidelines.

A national survey assessment compared against the 6-item "ABCDs of ASCVD prevention" show the significant prevalence of obesity.

Desai discusses the potential long-term effects of mavacamten and what it could mean for a patient population with HCM.

Investigators believe the novel monoclonal antibody may be a suitable agent in patients with major bleeding risk or those undergoing surgery.

Findings from SODIUM-HF suggest strategies to reduce dietary sodium intake to less than 1500 mg daily were not more effective than usual care in reducing hospitalization risk.

Findings from VALOR-HCM suggest more data is needed to assess the durability of improvement in septal reduction therapy eligibility over longer time periods.

New late-breaking ACC 2022 data support the use of antihypertensive therapy to reduce risk of events including preeclampsia and neonatal death among at-risk expecting mothers.

An investigator discusses new ACC 2022 data showing valvular heart disease is disparately impacting older patients, as well as females, with previously unanticipated manifestations.

Hospitalized HFrEF patients had a higher rate of the cardiovascular death or a worsening heart failure event than outpatients

Guideline writing committee co-chair Biykem Bozkurt, MD, PhD, discusses the utility of the drug class in HF prevention and risk reduction.

The NaV1.8 inhibitor VX-548 shows promising potential as a non-opioid acute pain treatment.

Using a main adjusted model, the investigators found an increase of 31.8 percentage points in test completion in the intervention group compared to the control group.

Previous research suggested that inpatient dermatology services not only improved diagnostic accuracy but reduced readmissions.

There are now more insulin options for patients with diabetes than ever before.

No specific inflammatory pathway was considered causative to long-term mortality in kidney transplant recipients.

Late use of steroids among patients with AIN shows now indication of further recovery and poses an additional risk of exposing patients to adverse effects.

Dr. Jabbour discusses unmet needs in diabetes care and starting insulin therapy.

The guidelines replace risk-based reccomendations for adults between 19-59 years.

Team-based care shows the reduction of multiple risk factors, attainment of multiple treatment targets, and empowerment among high-risk patients with DKD.

The costs related to Medicare for OACC increased by about 4% between 2012-2017 for patients with end-stage kidney disease for kidney transplantation.

When combined with corticosteroids, the oral therapy appeared to be as effective as IVCY with a more favorable safety profile.

A consensus was reached on nearly all proposals in the eDelphi study, which members said could be used to establish a clear dosing regimen for methotrexate.

The agency cited an increased risk of thromboembolic events driven by vascular access thrombosis in dialysis patients and increased risk of drug-induced liver injuries.

Males between 50-64 who have been vaccinated without erythema were at the highest risk of GBS.

Female academic ophthalmologists were paid a mean of $50,300 less than male peers.